Drug Discovery Today最新文献

筛选
英文 中文
Corrigendum to “Estimating the global inventory of deprioritized clinical-stage drug development programs: toward a market for shelved assets” [Drug Discov. Today 31(4) 2026 104723] 对“估计未优先考虑的临床阶段药物开发项目的全球库存:走向搁置资产市场”的更正[药物发现]。今日31(4)2026 104723]。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-09-01 Epub Date: 2026-08-05 DOI: 10.1016/j.drudis.2026.104747
Annette Bakker, Tanisha Carino, Joonhyuk Cho, Mosab Hammoudeh, Joshua L. Krieger, Freda Lewis-Hall, Andrew W. Lo, Richard T. Thakor
{"title":"Corrigendum to “Estimating the global inventory of deprioritized clinical-stage drug development programs: toward a market for shelved assets” [Drug Discov. Today 31(4) 2026 104723]","authors":"Annette Bakker, Tanisha Carino, Joonhyuk Cho, Mosab Hammoudeh, Joshua L. Krieger, Freda Lewis-Hall, Andrew W. Lo, Richard T. Thakor","doi":"10.1016/j.drudis.2026.104747","DOIUrl":"10.1016/j.drudis.2026.104747","url":null,"abstract":"","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"31 5","pages":"Article 104747"},"PeriodicalIF":8.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148597205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AI-augmented evidence as the next core competence in rare disease drug development: from snapshots to 360-degree movies 人工智能增强证据作为罕见病药物开发的下一个核心竞争力:从快照到360度电影。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-09-01 Epub Date: 2026-09-03 DOI: 10.1016/j.drudis.2026.104795
Ning Lu
{"title":"AI-augmented evidence as the next core competence in rare disease drug development: from snapshots to 360-degree movies","authors":"Ning Lu","doi":"10.1016/j.drudis.2026.104795","DOIUrl":"10.1016/j.drudis.2026.104795","url":null,"abstract":"<div><ul><li><span>•</span><span><div>AI could reconstruct probable disease trajectories from fragmented rare disease data.</div></span></li><li><span>•</span><span><div>The FDA and EMA issued joint artificial intelligence guiding principles in 2026, opening a defined pathway.</div></span></li><li><span>•</span><span><div>In one analysis, 94% of single-arm-trial products were nonassessable under European Union Joint Clinical Assessment.</div></span></li><li><span>•</span><span><div>Health technology assessment acceptance, not regulatory approval, is the binding constraint on patient access.</div></span></li><li><span>•</span><span><div>Data infrastructure plus artificial intelligence capability is the emerging rare disease competitive moat.</div></span></li></ul></div><div><div>Rare disease drug development generates fragmented evidence that often fails health technology assessment (HTA) standards. This article sets out a ‘snapshots to 360-degree movies’ framework: Reconstructing a disease course from patients each seen once, through autoencoders, data-driven disease staging and optimal transport. Each component has been demonstrated elsewhere—ordering in rare neurodegenerative disease, the others outside rare disease—but not yet together at patient-population scale; the article states the conditions under which it would fail. The binding constraint is not regulatory: Regulators are increasingly receptive, but HTA bodies remain the bottleneck, and the European Union’s Joint Clinical Assessment has put comparative evidence on the critical path—for most rare diseases, precisely what is missing. Building that capability may become a competitive advantage.</div></div><div>Rare disease drug development generates fragmented evidence that often fails health technology assessment (HTA) standards. This article sets out a ‘snapshots to 360-degree movies’ framework: Reconstructing a disease course from patients each seen once, through autoencoders, data-driven disease staging and optimal transport. Each component has been demonstrated elsewhere—ordering in rare neurodegenerative disease, the others outside rare disease—but not yet together at patient-population scale; the article states the conditions under which it would fail. The binding constraint is not regulatory: Regulators are increasingly receptive, but HTA bodies remain the bottleneck, and the European Union’s Joint Clinical Assessment has put comparative evidence on the critical path—for most rare diseases, precisely what is missing. Building that capability may become a competitive advantage.</div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"31 5","pages":"Article 104795"},"PeriodicalIF":8.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148885740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacological targeting of GCN5/PCAF (KAT2A/B): current drug discovery strategies and translational potential GCN5/PCAF (KAT2A/B)的药理靶向:当前的药物发现策略和转化潜力
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-09-01 Epub Date: 2026-08-20 DOI: 10.1016/j.drudis.2026.104778
Priyanka Pandey, Prajjval Mishra, Pritam Biswas, Sourav Chatterjee, Tapas K. Kundu
{"title":"Pharmacological targeting of GCN5/PCAF (KAT2A/B): current drug discovery strategies and translational potential","authors":"Priyanka Pandey,&nbsp;Prajjval Mishra,&nbsp;Pritam Biswas,&nbsp;Sourav Chatterjee,&nbsp;Tapas K. Kundu","doi":"10.1016/j.drudis.2026.104778","DOIUrl":"10.1016/j.drudis.2026.104778","url":null,"abstract":"&lt;div&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Structural, functional and evolutionary aspects of general control nonderepressible 5 (GCN5) and p300/CBP-associated factor (PCAF).&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Their roles in disease pathology and advances in inhibitor development are reviewd.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Small-molecule and natural product inhibitors, and next-generation chemical tools are discussed.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Outlines challenges in probe selectivity and clinical translation of catalytic and noncatalytic domain inhibitors.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;A framework for rational GCN5 and PCAF inhibitor development is proposed.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;The catalytic activity of general control non-derepressible 5 (GCN5) and p300/CBP-associated factor (PCAF) plays a pivotal role in numerous physiological and pathological conditions, underscoring its potential as a therapeutic target. However, developing clinically viable modulators remains challenging due to highly conserved catalytic domains within the GCN5-related &lt;em&gt;N&lt;/em&gt;-acetyltransferases family. Recent advances have shifted the focus from classical catalytic-site inhibitors to noncatalytic-domain inhibitors, improving selectivity and specificity. Emerging approaches, including proteolysis-targeting chimeras, acetylation-targeting chimeras, high-throughput screening and rational drug design, are reshaping the landscape of inhibitor development. This review outlines the structural features, functions and diverse roles of GCN5/PCAF in disease pathology, with an emphasis on inhibitor design strategies. We also propose a framework for inhibitor development that integrates active-site engagement, pharmacophore modelling and function-driven targeting strategies to bridge the gap between early-stage discovery and translational potential.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;The catalytic activity of general control non-derepressible 5 (GCN5) and p300/CBP-associated factor (PCAF) plays a pivotal role in numerous physiological and pathological conditions, underscoring its potential as a therapeutic target. However, developing clinically viable modulators remains challenging due to highly conserved catalytic domains within the GCN5-related &lt;em&gt;N&lt;/em&gt;-acetyltransferases family. Recent advances have shifted the focus from classical catalytic-site inhibitors to noncatalytic-domain inhibitors, improving selectivity and specificity. Emerging approaches, including proteolysis-targeting chimeras, acetylation-targeting chimeras, high-throughput screening and rational drug design, are reshaping the landscape of inhibitor development. This review outlines the structural features, functions and diverse roles of GCN5/PCAF in disease pathology, with an emphasis on inhibitor design strategies. We also propose a framework for inhibitor development that integrates active-site engagement, pharmacophore modelling and function-driven target","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"31 5","pages":"Article 104778"},"PeriodicalIF":8.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient experience data as a methodological and strategic innovation in clinical trial design 患者体验数据作为临床试验设计的方法论和战略创新。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-09-01 Epub Date: 2026-08-18 DOI: 10.1016/j.drudis.2026.104775
Alice Vanneste, Axelle Jankelevitch, Linda Lukeba, Peter Sinnaeve, Isabelle Huys, Tom Adriaenssens
{"title":"Patient experience data as a methodological and strategic innovation in clinical trial design","authors":"Alice Vanneste,&nbsp;Axelle Jankelevitch,&nbsp;Linda Lukeba,&nbsp;Peter Sinnaeve,&nbsp;Isabelle Huys,&nbsp;Tom Adriaenssens","doi":"10.1016/j.drudis.2026.104775","DOIUrl":"10.1016/j.drudis.2026.104775","url":null,"abstract":"<div><ul><li><span>•</span><span><div>Stakeholders increasingly recognise the value of integrating the patient perspective in drug development.</div></span></li><li><span>•</span><span><div>Patient experience data have the potential to strengthen endpoint science and patient-centred trial design.</div></span></li><li><span>•</span><span><div>Early and structured patient experience data integration can improve trial efficiency and real-world relevance.</div></span></li><li><span>•</span><span><div>Harmonisation, standardisation and innovation are needed to enhance robust patient experience data implementation.</div></span></li><li><span>•</span><span><div>Patient experience data represent a methodological and strategic innovation in clinical trial design to align evidence with patients’ needs and preferences.</div></span></li></ul></div><div><div>Patient experience data (PED) are increasingly recognised as a methodological and strategic innovation in drug development, yet their implementation in clinical trial design remains inconsistent. Drawing on a structured literature review and multistakeholder interviews, this analysis examines how PED inform endpoint decision-making. Although clinical development is shifting towards more patient-informed measures, challenges persist due to limited standardisation, validation, methodological gaps and operational constraints. Opportunities include early patient involvement, validated disease-specific measures, consensus-based core outcome sets and clearer regulatory guidance, enabling meaningful and structured PED implementation that strengthens evidence generation, reduces development risk and improves trial efficiency and real-world relevance.</div></div><div>Patient experience data (PED) are increasingly recognised as a methodological and strategic innovation in drug development, yet their implementation in clinical trial design remains inconsistent. Drawing on a structured literature review and multistakeholder interviews, this analysis examines how PED inform endpoint decision-making. Although clinical development is shifting towards more patient-informed measures, challenges persist due to limited standardisation, validation, methodological gaps and operational constraints. Opportunities include early patient involvement, validated disease-specific measures, consensus-based core outcome sets and clearer regulatory guidance, enabling meaningful and structured PED implementation that strengthens evidence generation, reduces development risk and improves trial efficiency and real-world relevance.</div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"31 5","pages":"Article 104775"},"PeriodicalIF":8.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rare disease benchmarks: Investment professionals’ accuracy and beliefs 罕见病基准:投资专业人士的准确性和信念。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-09-01 Epub Date: 2026-08-31 DOI: 10.1016/j.drudis.2026.104792
Jonathan Ilicki, Alexander J. Spicer
{"title":"Rare disease benchmarks: Investment professionals’ accuracy and beliefs","authors":"Jonathan Ilicki,&nbsp;Alexander J. Spicer","doi":"10.1016/j.drudis.2026.104792","DOIUrl":"10.1016/j.drudis.2026.104792","url":null,"abstract":"&lt;div&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Practitioners knew rare-disease assets differ but often missed the benchmarks.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Acquisition time was miscalibrated with assets acquired later than expected.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;84% underestimated that most rare-disease launches meet or exceed expectations.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Estimate accuracy did not improve with years of experience.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;General benchmarks seem to be used instead of rare-disease benchmarks.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Rare-disease assets account for a substantial and growing share of biopharmaceutical development and dealmaking, and published analyses provide benchmarks for their clinical, commercial and financial performance. Whether investment and business-development practitioners hold beliefs consistent with these benchmarks is largely unexamined. We surveyed 43 professionals across venture capital, pharmaceutical and biotechnology business development, asking them to estimate benchmarks for approval probability, acquisition timing, exit economics, time to peak sales and launch performance, and compared their responses with the published literature. Respondents were generally well calibrated on some structural characteristics visible through deal flow, such as the dominant modality for rare-disease assets, but systematically miscalibrated on specific magnitudes. Launch performance was the most underestimated, with 84% placing it below published levels, and most respondents underestimating how late acquisitions of rare-disease assets occur. Estimate accuracy was not associated with years of experience. These findings suggest a wide gap between published evidence and practitioner belief, which might lead some rare-disease assets to be assessed more conservatively than historical performance would justify.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Rare-disease assets account for a substantial and growing share of biopharmaceutical development and dealmaking, and published analyses provide benchmarks for their clinical, commercial and financial performance. Whether investment and business-development practitioners hold beliefs consistent with these benchmarks is largely unexamined. We surveyed 43 professionals across venture capital, pharmaceutical and biotechnology business development, asking them to estimate benchmarks for approval probability, acquisition timing, exit economics, time to peak sales and launch performance, and compared their responses with the published literature. Respondents were generally well calibrated on some structural characteristics visible through deal flow, such as the dominant modality for rare-disease assets, but systematically miscalibrated on specific magnitudes. Launch performance was the most underestimated, with 84% placing it below published levels, and most respondents underestimating how late acquisitions of rare-disease assets occ","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"31 5","pages":"Article 104792"},"PeriodicalIF":8.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148862883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sustainable drug delivery systems: Biodegradable carriers for a carbon–neutral pharma future 可持续药物输送系统:生物可降解载体的碳中性制药未来。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-09-01 Epub Date: 2026-08-19 DOI: 10.1016/j.drudis.2026.104780
Wasim Akram, Kantrol Kumar Sahu
{"title":"Sustainable drug delivery systems: Biodegradable carriers for a carbon–neutral pharma future","authors":"Wasim Akram,&nbsp;Kantrol Kumar Sahu","doi":"10.1016/j.drudis.2026.104780","DOIUrl":"10.1016/j.drudis.2026.104780","url":null,"abstract":"<div><ul><li><span>•</span><span><div>Biodegradable carriers reduce environmental impact while maintaining therapeutic performance.</div></span></li><li><span>•</span><span><div>Polysaccharides, PHAs, and PLA enable tunable degradation and sustainable drug delivery.</div></span></li><li><span>•</span><span><div>Smart nanocarriers enable precision-controlled drug release through multiple stimuli.</div></span></li><li><span>•</span><span><div>Green manufacturing uses renewable feedstocks, enzymatic processing, and solvent-free methods.</div></span></li><li><span>•</span><span><div>AI and lifecycle assessment support circular and carbon-conscious pharmaceutical development.</div></span></li></ul></div><div><div>The growing emphasis on sustainable healthcare has accelerated the development of biodegradable drug delivery systems (DDS) as environmentally responsible alternatives to conventional polymeric carriers. Natural biopolymers and biodegradable synthetic polymers offer biocompatibility, controlled degradation and the potential to reduce long-term environmental burden when combined with green manufacturing and life-cycle-based design. Recent advances in nanoscale engineering, stimuli-responsive delivery and sustainable synthesis have further enhanced their therapeutic performance. However, challenges, including raw material variability, inconsistent degradation, manufacturing scalability, regulatory standardization and limited life cycle assessment, remain barriers to widespread clinical translation. Addressing these challenges through interdisciplinary innovation, green chemistry and harmonized regulatory frameworks will facilitate the development of high-performance, sustainable DDS that support a more environmentally responsible pharmaceutical industry.</div></div><div>The growing emphasis on sustainable healthcare has accelerated the development of biodegradable drug delivery systems (DDS) as environmentally responsible alternatives to conventional polymeric carriers. Natural biopolymers and biodegradable synthetic polymers offer biocompatibility, controlled degradation and the potential to reduce long-term environmental burden when combined with green manufacturing and life-cycle-based design. Recent advances in nanoscale engineering, stimuli-responsive delivery and sustainable synthesis have further enhanced their therapeutic performance. However, challenges, including raw material variability, inconsistent degradation, manufacturing scalability, regulatory standardization and limited life cycle assessment, remain barriers to widespread clinical translation. Addressing these challenges through interdisciplinary innovation, green chemistry and harmonized regulatory frameworks will facilitate the development of high-performance, sustainable DDS that support a more environmentally responsible pharmaceutical industry.</div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"31 5","pages":"Article 104780"},"PeriodicalIF":8.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Signaling execution readiness: The evolving leadership requirements for biotech fundraising 信号执行准备:生物技术融资不断变化的领导力要求。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-09-01 Epub Date: 2026-08-24 DOI: 10.1016/j.drudis.2026.104787
Keita Kiriya, Sotaro Shibayama
{"title":"Signaling execution readiness: The evolving leadership requirements for biotech fundraising","authors":"Keita Kiriya,&nbsp;Sotaro Shibayama","doi":"10.1016/j.drudis.2026.104787","DOIUrl":"10.1016/j.drudis.2026.104787","url":null,"abstract":"<div><ul><li><span>•</span><span><div>Biotech startups must prove execution readiness to secure funding.</div></span></li><li><span>•</span><span><div>Early-stage teams need industry veterans to validate scientific translation.</div></span></li><li><span>•</span><span><div>Founder-scientist CEOs in later stages severely limit access to capital.</div></span></li><li><span>•</span><span><div>Later-stage startups gain funding premiums with medical degrees or ex-pharma CEOs.</div></span></li><li><span>•</span><span><div>Evolving startup leadership helps reduce perceived execution risk.</div></span></li></ul></div><div><div>In a selective global biotech funding environment characterized by a ‘flight to quality’, startups must signal execution readiness to secure capital. Based on a dataset of Japanese drug discovery startups, we examine how management teams’ professional and educational backgrounds relate to fundraising performance, finding stage-dependent patterns. Early-stage startups are predominantly academic-led, yet raise less than those led by pharmaceutical veterans. In later stages, CEOs with purely academic backgrounds are associated with lower funding, whereas CEOs with medical degrees or pharmaceutical experience are associated with higher funding. Retaining academic founder-CEOs early might also introduce governance and conflict-of-interest risks. These results are consistent with a view that leadership should evolve as firms mature—incorporating industry professionals early and, potentially, transitioning founder-CEOs before late-stage transitions.</div></div><div>In a selective global biotech funding environment characterized by a ‘flight to quality’, startups must signal execution readiness to secure capital. Based on a dataset of Japanese drug discovery startups, we examine how management teams’ professional and educational backgrounds relate to fundraising performance, finding stage-dependent patterns. Early-stage startups are predominantly academic-led, yet raise less than those led by pharmaceutical veterans. In later stages, CEOs with purely academic backgrounds are associated with lower funding, whereas CEOs with medical degrees or pharmaceutical experience are associated with higher funding. Retaining academic founder-CEOs early might also introduce governance and conflict-of-interest risks. These results are consistent with a view that leadership should evolve as firms mature—incorporating industry professionals early and, potentially, transitioning founder-CEOs before late-stage transitions.</div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"31 5","pages":"Article 104787"},"PeriodicalIF":8.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148811731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating population heterogeneity in drug research and early development: a proactive strategy 在药物研究和早期开发中整合人口异质性:一个积极的策略。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-09-01 Epub Date: 2026-08-27 DOI: 10.1016/j.drudis.2026.104790
Thierry Lavé, Bruno Jolain, Ken Wang, Léa-Isabelle Proulx, Cristina Santini, Juliana Bessa, Valerie Crowell, Patricia Sanwald-Ducray, Ruma Bhagat, Nicole Richie
{"title":"Integrating population heterogeneity in drug research and early development: a proactive strategy","authors":"Thierry Lavé,&nbsp;Bruno Jolain,&nbsp;Ken Wang,&nbsp;Léa-Isabelle Proulx,&nbsp;Cristina Santini,&nbsp;Juliana Bessa,&nbsp;Valerie Crowell,&nbsp;Patricia Sanwald-Ducray,&nbsp;Ruma Bhagat,&nbsp;Nicole Richie","doi":"10.1016/j.drudis.2026.104790","DOIUrl":"10.1016/j.drudis.2026.104790","url":null,"abstract":"<div><ul><li><span>•</span><span><div>Proactive strategies shift focus from demographics to mechanistic heterogeneity.</div></span></li><li><span>•</span><span><div>The ‘anticipate-verify-influence’ framework de-risks early drug development.</div></span></li><li><span>•</span><span><div>Digital twins and organoids capture variability before late-stage clinical trials.</div></span></li><li><span>•</span><span><div>Inclusive R&amp;D improves technical success rates and meets new FDORA mandates.</div></span></li></ul></div><div><div>Population heterogeneity in disease biology, drug exposure and treatment response is often addressed only after development has progressed, limiting generalizability and increasing late-stage risk. We propose an anticipate-verify-influence framework to integrate clinically relevant variability from research through development. The approach combines diverse human-derived models, real-world data, model-informed drug development and AI/ML to identify drivers of heterogeneity, test their clinical relevance early and translate validated findings into trial design, dosing and patient selection. Rather than pursuing demographic representation alone, the framework emphasizes mechanistic and quantitative understanding of intrinsic and extrinsic determinants of response. Earlier characterization of meaningful heterogeneity could improve development decisions, trial representativeness and evidence generation for patients who are frequently underrepresented.</div></div><div>Population heterogeneity in disease biology, drug exposure and treatment response is often addressed only after development has progressed, limiting generalizability and increasing late-stage risk. We propose an anticipate-verify-influence framework to integrate clinically relevant variability from research through development. The approach combines diverse human-derived models, real-world data, model-informed drug development and AI/ML to identify drivers of heterogeneity, test their clinical relevance early and translate validated findings into trial design, dosing and patient selection. Rather than pursuing demographic representation alone, the framework emphasizes mechanistic and quantitative understanding of intrinsic and extrinsic determinants of response. Earlier characterization of meaningful heterogeneity could improve development decisions, trial representativeness and evidence generation for patients who are frequently underrepresented.</div><div>Anticipate–verify–influence framework for proactive integration of population heterogeneity.</div><div><span><figure><span><img><ol><li><span><span>Download: <span>Download high-res image (122KB)</span></span></span></li><li><span><span>Download: <span>Download full-size image</span></span></span></li></ol></span></figure></span></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"31 5","pages":"Article 104790"},"PeriodicalIF":8.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148838502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence agents and agentic artificial intelligence applied to precision medicine 人工智能代理和代理人工智能应用于精准医疗。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-09-01 Epub Date: 2026-08-19 DOI: 10.1016/j.drudis.2026.104781
Fabricio F. Costa
{"title":"Artificial intelligence agents and agentic artificial intelligence applied to precision medicine","authors":"Fabricio F. Costa","doi":"10.1016/j.drudis.2026.104781","DOIUrl":"10.1016/j.drudis.2026.104781","url":null,"abstract":"<div><ul><li><span>•</span><span><div>Agentic AI integrates autonomy, memory, planning and tool use across drug discovery.</div></span></li><li><span>•</span><span><div>First AI-discovered drug rentosertib advances toward Phase III trials in IPF (2026).</div></span></li><li><span>•</span><span><div>Multi-agent systems now outperform expert physicians in rare disease diagnostics.</div></span></li><li><span>•</span><span><div>AlphaGenome and Evo 2 reshape variant interpretation at megabase resolution.</div></span></li><li><span>•</span><span><div>Model hallucinations and sociodemographic bias remain critical safety barriers.</div></span></li></ul></div><div><div>Precision medicine seeks to individualise care by integrating multimodal biomedical data, yet most deployed clinical artificial intelligence (AI) remains assistive, providing predictions without managing workflows or adapting autonomously. Agentic AI, built on large language models (LLMs), has emerged as a paradigm characterised by autonomy, goal-directed reasoning, memory, planning and tool use. This review synthesises evidence on agentic AI and LLMs applied to precision medicine, encompassing drug discovery, genomics, oncology, rare disease diagnostics and clinical pharmacology. This review also examines architectural components, recent validation milestones and emerging challenges, including hallucination, sociodemographic bias and evolving regulatory frameworks across the FDA, the EU AI Act and the WHO.</div></div><div>Precision medicine seeks to individualise care by integrating multimodal biomedical data, yet most deployed clinical artificial intelligence (AI) remains assistive, providing predictions without managing workflows or adapting autonomously. Agentic AI, built on large language models (LLMs), has emerged as a paradigm characterised by autonomy, goal-directed reasoning, memory, planning and tool use. This review synthesises evidence on agentic AI and LLMs applied to precision medicine, encompassing drug discovery, genomics, oncology, rare disease diagnostics and clinical pharmacology. This review also examines architectural components, recent validation milestones and emerging challenges, including hallucination, sociodemographic bias and evolving regulatory frameworks across the FDA, the EU AI Act and the WHO.</div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"31 5","pages":"Article 104781"},"PeriodicalIF":8.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paediatric Regulation in the European Union: an overview 欧盟儿科法规:概述。
IF 8.7 2区 医学
Drug Discovery Today Pub Date : 2026-09-01 Epub Date: 2026-08-18 DOI: 10.1016/j.drudis.2026.104777
Paolo Caferra, Thomas Fraisse, Veronica Baffa, Eva Kalfon, Andrea Salzano, Maria Letizia Trincavelli, Laura Marchetti, Anna Maria Piras
{"title":"Paediatric Regulation in the European Union: an overview","authors":"Paolo Caferra,&nbsp;Thomas Fraisse,&nbsp;Veronica Baffa,&nbsp;Eva Kalfon,&nbsp;Andrea Salzano,&nbsp;Maria Letizia Trincavelli,&nbsp;Laura Marchetti,&nbsp;Anna Maria Piras","doi":"10.1016/j.drudis.2026.104777","DOIUrl":"10.1016/j.drudis.2026.104777","url":null,"abstract":"<div><ul><li><span>•</span><span><div>PIPs are the cornerstone of EU paediatric healthcare policy.</div></span></li><li><span>•</span><span><div>Waivers and deferrals are integral tools, not exceptions, of drug development.</div></span></li><li><span>•</span><span><div>PIPs channel paediatric studies into a structured regulatory framework.</div></span></li><li><span>•</span><span><div>Compliance data reveal enduring operational challenges in PIP execution.</div></span></li><li><span>•</span><span><div>The new EU pharmaceutical legislation package could reshape incentives for the paediatric medicinal product advancement.</div></span></li></ul></div><div><div>Paediatric Investigation Plans (PIPs) are a critical component of the EU’s regulatory strategy to ensure that medicines are appropriately studied, developed and authorised for use in children. The legislative scheme for PIPs was established under Regulation (EC) no. 1901/2006, also known as ‘Paediatric Regulation’. Paediatric Regulation mandates that all new marketing authorisation applications and line extensions must include data from PIPs unless waivers or deferrals have been granted. This literature review’s objective is to explore the ‘PIPs, waivers and deferrals’ regulatory framework for on- and off-patent drugs and provide a glimpse of the new ‘pharma package’ upcoming changes.</div></div><div>Paediatric Investigation Plans (PIPs) are a critical component of the EU’s regulatory strategy to ensure that medicines are appropriately studied, developed and authorised for use in children. The legislative scheme for PIPs was established under Regulation (EC) no. 1901/2006, also known as ‘Paediatric Regulation’. Paediatric Regulation mandates that all new marketing authorisation applications and line extensions must include data from PIPs unless waivers or deferrals have been granted. This literature review’s objective is to explore the ‘PIPs, waivers and deferrals’ regulatory framework for on- and off-patent drugs and provide a glimpse of the new ‘pharma package’ upcoming changes.</div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"31 5","pages":"Article 104777"},"PeriodicalIF":8.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书